WG
ITCI

Winton Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Winton Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,527
Closed -$245K – 1169
2023
Q1 		$245K Buy
+4,527
New +$219K 0.01% 863
2021
Q4 		– Sell
-11,369
Closed -$424K – 1468
2021
Q3 		$424K Buy
11,369
+4,516
+66% +$157K 0.02% 940
2021
Q2 		$280K Sell
6,853
-3,953
-37% -$146K 0.02% 1215
2021
Q1 		$367K Buy
+10,806
New +$375K 0.02% 1045

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Winton Group's ITCI Position: Q2 2023 in Review

Winton Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 4,527 shares — an estimated $245K sold.

Winton Group first reported a position in ITCI in Q1 2021 and held it in 4 quarters. The position peaked at $424K in Q3 2021. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Winton Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Winton Group sold 4,527 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $245K.
  • Winton Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2021 and held it in 4 quarters.
  • Winton Group's Intra-Cellular Therapies Inc. position peaked at $424K in Q3 2021.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Winton Group's 13F filing for Q2 2023, filed 14 Aug 2023.